We serve Chemical Name:(3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)butanoic acid CAS:868071-17-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)butanoic acid
CAS.NO:868071-17-4
Synonyms:(S)-3-Hydroxy-4-(2,4,5-trifluorophenyl)butanoic acid;(S)-3-hydroxy-4-(2,4,5-trifluorophenyl)butyric acid;4-(2,4,5-trifluorophenyl)-3(S)-hydroxybutanoic acid;(3S)-2′,4′,5′-Trifluoro-3-hydroxybenzenebutanoic acid;3(S)-4-(2,4,5-trifluorophenyl)-3-hydroxybutanoic acid;(3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid;3(S)-4-(2,4,5-trifluorophenyl)-3-hydroxybenzenebutanoic acid
Molecular Formula:C10H9F3O3
Molecular Weight:234.17200
HS Code:2918199090
Physical and Chemical Properties:
Melting point:87ºC
Boiling point:N/A
Density:1.459 g/cm3
Index of Refraction:
PSA:57.53000
Exact Mass:234.05000
LogP:1.48200
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (S)-3-Hydroxy-4-(2,4,5-trifluorophenyl)butanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3(S)-4-(2,4,5-trifluorophenyl)-3-hydroxybenzenebutanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(S)-3-Hydroxy-4-(2,4,5-trifluorophenyl)butanoic acid Use and application,(3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)-butyric acid technical grade,usp/ep/jp grade.
Related News: The program caused the price of some drugs to plunge more than 90% when it was introduced last year in some cities, state news agency Xinhua said. (3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)butanoic acid manufacturer The Environmental Working Group, a nonprofit advocacy organization, applauded the bill’s introduction. (3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)butanoic acid supplier Darzalex has its own VRd combo trials, dubbed PERSEUS and CEPHEUS, which are testing a newly approved under-the-skin version of the J&J drug called Darzalex Faspro. The CEPHEUS trial appears to have just completed its primary analysis, according to a listing on ClinicalTrials.gov. (3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)butanoic acid vendor Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037. (3S)-3-hydroxy-4-(2,4,5-trifluorophenyl)butanoic acid factory The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD.
